Development and Presentation Faculty
Leslie L. Davis, PhD, RN, ANP-BC
Assistant Professor of Nursing
University of North Carolina, Greensboro
Clinical Assistant Professor of Medicine
University of North Carolina, Chapel Hill
Chapel Hill, NC
Additional Development Faculty
Andrew Krumerman, MD
Associate Professor of Clinical Medicine
Albert Einstein College of Medicine
Cardiology, Arrhythmia Service
Montefiore Medical Center
1.0 contact hour of continuing education (which includes 0.8 hours of pharmacology)
Nonvalvular atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and afflicts more than 3 million people in the United States. AF is an independent risk factor for ischemic stroke severity, recurrence, and mortality. Individuals with AF have a 4 to 5 times greater risk for ischemic stroke. The National Stroke Association emphasizes the importance of treatment to prevent stroke in patients with AF, noting that patients tend to experience worse outcomes from AF-related stroke compared with non-AF-related stroke. Although most AF-related strokes can be prevented with antithrombotic therapy, many patients with AF are not receiving optimal evidence-based care for stroke prevention. Patients with AF whose clinicians are not up to date with the current best practices for stroke prevention are at risk of experiencing suboptimal outcomes. This activity will increase NPs’ ability to incorporate into clinical practice the latest evidence-based recommendations for implementing and tailoring antithrombotic therapy.
Developed by the American Association of Nurse Practitioners in cooperation with
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
- Apply evidence-based scoring assessments to properly risk stratify patients with atrial fibrillation, considering stroke and bleeding risks.
- Discuss key differences in the pharmacologic profiles of the new oral anticoagulants that may impact selection of a specific agent for an individual patient with atrial fibrillation.
- Select the correct dosage for oral anticoagulant therapy for patients with atrial fibrillation and renal impairment.
- Develop individualized guideline-based antithrombotic treatment regimens for stroke prevention in patients with atrial fibrillation.
Leslie L. Davis, PhD, RN, ANP-BC, FAANP, FAHA, has no conflicts of interest to disclose.
Andrew Krumerman, MD, has no conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
This program is approved for 1.0 contact hour of continuing education (which includes 0.8 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 15111981.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
COMPLETING THE POST TEST AND EVALUATION:
- When you return to the AANP CE Center, log in and find the program you wish to complete. On the program’s content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.
- If you do not have a registration (email and password) with AANP, you will be asked to register: MyAANP. Complete the short profile and create your password to continue in the CE Center. Please contact Stormy Causey, CE Coordinator, at CECenter@aanp.org with any questions.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Association of Nurse Practitioners, or Boehringer Ingelheim Pharmaceuticals, Inc.